Subscribe via E-mail

Your email:
subscribe-to-our-newsletter
alcoa-checklist
watch-fair-shake-video-4-point-guideline-to-navigate-through-regulations

Medical Device CRO Blog

Current Articles | RSS Feed RSS Feed

How Improper Consent Can Lead to a Warning Letter

  
  
  

Improper Informed Consent (2)While working on a recent project involving researching FDA warning letters, it astonished me the number of investigators and investigative sites who had issues with informed consent.  I was surprised at the seemingly little familiarity study staff had regarding Federal Regulations when it came to the informed consent and the consenting process.

Many of the warning letters referenced consent issues such as failing to obtain consent according to 21 CFR 50 by:

  1. Not obtaining informed consent prior to any study procedures
  2. Not using an informed consent approved by the IRB
  3. Failing to obtain informed consent at all

Who is ultimately responsible for training investigators and study staff on how to properly obtain and document informed consent?

According to 21 CFR 812.00, “An investigator is responsible for….protecting the rights, safety and welfare of subjects under the investigator’s care…..”  Failure to properly obtain informed consent is a failure to protect subjects.  Every investigator should know that a subject has a properly signed and dated consent form prior to administering an investigational product or implanting an investigational device.  In the clinical setting, a patient cannot get on the table in the OR without a properly signed, dated, and documented consent form.  There are many checks and balances… from surgeons, nurses, anesthesiologists, etc. The consent is that patient’s ticket to the table.

So why do investigators, the majority of whom are physicians, fall short when consenting subjects for research?   One thing, of course, is it is not always the investigator who consents the subject.  However, according to 21 CFR 812.100, “An investigator also is responsible for ensuring that informed consent is obtained in accordance with part 50…” Ultimately, the investigator is responsible for informed consent and he/she must always be aware of what the study staff is or is not doing.  This is how the investigator performs oversight of the clinical trial.  By reading a number of warning letters, it was clear that investigators did not always have a tight grip on “oversight” (a topic for another blog…).

Per the regulations, the Investigator bears all responsibility for consenting (among other things), and anyone becoming an Investigator should be familiar with the regulations they have to follow.  However, based on these findings, somehow we are still falling short.  Maybe there needs to be a standardized, documented training procedure in place to be completed by all study staff working in research who are delegated the responsibility of consenting subjects.

What are your experiences with informed consent?  How can we ensure proper consenting takes place?  Please share your thoughts and ideas with us.

Photo Credit: Andy on Flickr

Comments

Thank you for this post! 
 
 
 
From my experience, I noticed that many investigators are relying to much on CROs and study sponsors to take care of the informed consent process and do not even bother to review the form and see if it covers all the required issues (procedures, SAEs, etc.). 
 
 
 
Investigators should involve themselves more in this process and make sure that the information is complete - and more importantly, that the patient is able to understand it. Investigators should make sure that informed consent forms are written in simple language which patients can understand, and in the patient's own language - it is highly unethical to present a patient who doesn't read English with an English consent form, and hope that he will be able to read it! 
 
 
 
I hope that the both investigators and CRO's take these issues under consideration, thus creating a more ethical trial and saving themselves the FDA warning letters.
Posted @ Tuesday, June 19, 2012 1:34 AM by Matan Topper-Erez
Thank you for you comment. This is a great point- as part of showing PI oversight, investigators should review their informed consent documents to ensure that all essential elements are present (rather than the CRO or Sponsor catching missing elements later on, after patients have been consented!) Would you consider the PI “reviewing” these documents when they are signing off on IRB submissions? Would you have any suggestions as to how the PI would also oversee the informed consent process, to ensure that it is done appropriately (i.e. your example of non-English speaking patients being given English consent documents)?
Posted @ Wednesday, June 20, 2012 1:44 PM by Stephani Hulec
Dear John 
 
ICH GCP says that investigators should be qualified through experience, training and education. I have asked myself many a time: Does this refer to the medical degree or does it put an onus on the investigator to further educate him/herself in the field of clinical research? I am currently studying and for an assignment had to draw up an informed consent document and also state exactly what the informed consent process entails. Recently I was asked to review a new trial's informed consent document at work. I don't think many people realize that you should check an informed consent to see if it meets about 50 elements. I think investigators need to do courses and educate themselves, a simple GCP course is not adequate and what sponsor or CRA have time to do such detailed specific training? Fact is that new sub-investigators are clueless as to how to approach clinical research and divorce the bad habits they fostered in private general practice. Is it time to do make additional clinical research relevant training compulsory? I think it is, patients safety demands it. Regards, Magda
Posted @ Monday, June 25, 2012 9:01 AM by Magda Bakker
Hi, 
 
 
 
the reality is that most investigators have very little oversight on studies. The Informed Consent is often obtained by the study coordinator. I am very scrupolous in checking I/E criteria and correct ICF completion. I make sure that the PI takes time to talk to me even if for just a few minutes to let him know of any issues. An ICF issue MUST be taken to the PI and and the PI must understand that an ICF violation is very serious! There are other issues which must be taken to the PI, i.e. failure for the study team to respect their role as described in the site signature and delegation log, failure to report to the IRB/Ethic Commission of major protocol deviations or repetitive protocol deviations which may put the subjects at risk or may invalidate study data, failure to train staff on Protocol/IB Amendements etc. The usual PI will not have a good oversight on a study, it is the responsibility of a good CRO/Monitor however to make sure that the PI takes responsibility.
Posted @ Wednesday, July 04, 2012 7:26 PM by Roberto de Filippo
I disagree. It is ALL of our responsibility to make the Investigator aware of his/her responsibilities under the federal regulations, under conditions of IRB approval for study conduct and ultimately the responsibility to the study participants, without WHOM no study would progress. In my opinion, an investigator who takes a completely hands-off approach to research, probably is too busy/overcommitted to be conducting research in the first place. Now don’t get me wrong, there is nothing wrong about delegating responsibility to appropriately qualified and trained staff- and usually it is the staff who keeps the study on track to completion. But even delegated study activities ultimately rest on the investigator. No one person can make another do what should be done. What we can do is re-direct an Investigator back into compliance or suggest that non-compliant Investigators be restricted from conducting research. The most central person to a study is the PATIENT. We must go to work everyday with their best interests front and center.
Posted @ Friday, July 06, 2012 10:22 AM by Mary Lewis
Post Comment
Name
 *
Email
 *
Website (optional)
Comment
 *

Allowed tags: <a> link, <b> bold, <i> italics